CSF3 and endometrial cancer: Consistent with these findings, MDSC-targeting treatments, such as anti-Gr-1 antibody treatment or splenectomy, had significant antitumor effects in mouse models of G-CSF-expressing, TRL-positive cervical and endometrial cancers that exhibited increased MDSC [21,28,29].